Cardiovascular disease (CVD), which incorporates coronary heart disease (CHD) and stroke, is the main cause of death worldwide^[@bibr1-2381468316671724]^ and in England and Wales.^[@bibr2-2381468316671724]^ Hypertension, defined as a persistent raised blood pressure (BP) of 140/90 mmHg,^[@bibr3-2381468316671724]^ has been recognized as the most important modifiable risk factor for CVD.^[@bibr2-2381468316671724],[@bibr3-2381468316671724]^ Poorly controlled high BP can damage artery walls and increase the risk of developing a blood clot. Moreover, if it is not treated it can also damage organs such as the kidneys, heart, and brain. Decision-analytic modeling (DAM) guidelines have recognized that randomized controlled clinical trials (RCTs) are good sources of evidence to judge the effectiveness of treatments; however, because the time horizon for trials often does not reflect the full duration of the impact of interventions, DAM is used to extend the results of a short-term trial over a longer time horizon.^[@bibr4-2381468316671724],[@bibr5-2381468316671724]^ A primary outcome used in RCTs that are focused on hypertension is often change in BP. However, this is only an intermediate outcome, and DAM can be used to examine the impact of change in BP on the risk of CVD events in the longer term.

Previous research has identified the need for further investigation into the compliance of DAM to good practice and its impact on the conclusions drawn from economic evaluations.^[@bibr6-2381468316671724]^ Our aim is to critically evaluate how DAM in primary prevention of CVD conforms to guidelines and, in doing so, validate a framework previously developed to assess compliance to guidelines. The focus here is on one particular clinical area since this makes it possible to remove some of the variation between models that is not relevant for the purpose of assessing compliance (e.g., different outcomes, treatment options, or sources of uncertainty). CVD prevention has been selected due to the wide number of recent and available model-based cost-effectiveness studies conducted in this topic area. We focused on interventions aimed at lowering BP, as a modifiable risk factor for CVD, and sought to answer the following research question: "To what extent do model-based economic evaluations of primary prevention interventions aimed at lowering BP in patients with hypertension or at risk of developing hypertension conform to the published guidelines for DAM?"

Methods {#section1-2381468316671724}
=======

Studies of interventions aimed at lowering BP were reviewed and the challenges faced when applying DAM methods were identified and discussed. A systematic review was conducted, meeting the UK Centre for Review and Dissemination guidance and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reporting.^[@bibr7-2381468316671724]^

The review followed a structured approach for framing research questions: patient population (P), intervention (I), the comparator group (C), outcome (O), and the study design (S), or PICOS.^[@bibr7-2381468316671724]^ Articles published from January 2000 to March 2015 and written in English were included in this review if they met all of the following conditions:

-   The target population was individuals presenting with high BP or at risk of developing hypertension

-   The intervention(s) aimed at lowering BP

-   Management of hypertension, as a modifiable risk factor for CVD, was part of a primary prevention strategy (when studies also included secondary prevention, we have concentrated on the results for primary prevention)

-   The study was a model-based economic evaluation

This review excluded systematic reviews, guidelines, trials, protocols, and conference abstracts. In addition, we also excluded studies where the interventions

-   Were aimed at screening BP

-   Were part of a polypill strategy

-   Measured nonadherence to treatment

-   Were part of a secondary prevention and treatment strategy

Searches were undertaken using terms identified by expert clinical opinion and a list of synonyms identified for each term that helped inform the final search terms used in this review ("cost effectiveness," "mathematical model," "decision analysis," "Markov model," "decision tree," "economic evaluation," "hypertension," and "lowering blood pressure"). The search was undertaken using truncations and wildcards, and all synonyms were subsequently combined with appropriate medical subject heading terms (MeSH) or subject terms using Boolean operators (see Online Appendices 1 and 2).

The following databases were searched: EMBASE and Medline via the Ovid interface, and the Centre for Reviews and Dissemination's (CRD) NHS Economic Evaluation Database (NHS-EED). In addition, we manually examined the reference lists of the studies included in this review. All articles identified by database searching were exported into ENDNOTE-X7 and duplicate references were removed.

Titles identified by the searches were screened by reading the abstract; this activity was completed by two reviewers (SJ and CP). Articles that appeared to be relevant at this point were obtained and screened against the inclusion and exclusion criteria (CP); several articles appeared relevant on reading the abstract but were subsequently excluded after reading the full article.

All studies were manually searched and data were extracted by a single reviewer (CP); any doubtful point(s) were checked with at least one another reviewer.^[@bibr6-2381468316671724]^ The extraction tool consisted of a framework^[@bibr6-2381468316671724]^ that synthesizes contemporary DAM guidelines in a single checklist instrument; this framework was developed to aid researchers assessing adherence to guidelines. The tool aided the retrieval and organization of information from each study across five dimensions (see Online Appendix 3):

1.  Problem concept

2.  Model concept

3.  Synthesis of evidence

4.  Analysis of uncertainty

5.  Model transparency and validation

This approach ensured that the review did not miss any information related to the model building process. Data were extracted as free text and in the form of a "yes/no" response.

Results {#section2-2381468316671724}
=======

The database search yielded 2607 studies; after removing 27 duplicates, 2580 studies were left for screening. A total of 2549 studies were excluded because they did not consider a CVD-related intervention, were not a model-based economic evaluation, or were focused on screening ([Figure 1](#fig1-2381468316671724){ref-type="fig"}). Thirty-one full-text articles were assessed for eligibility, of which 18 were rejected as a secondary prevention strategy. Thirteen studies were included in this review, none of which were identified through other sources ([Figure 1](#fig1-2381468316671724){ref-type="fig"}).

![Flow chart using the PRISMA statement for the systematic review.](10.1177_2381468316671724-fig1){#fig1-2381468316671724}

Only two of the studies included were published prior to 2004. Thus, it can be seen that the majority of studies (11/13) would have had access to DAM guidelines at the time of their publication (e.g., Weinstein and others^[@bibr8-2381468316671724]^ or Philips and others^[@bibr9-2381468316671724]^).

Four studies evaluated programs for the clinical prevention and treatment of hypertension^[@bibr10-2381468316671724][@bibr11-2381468316671724][@bibr12-2381468316671724]--[@bibr13-2381468316671724]^ and nine evaluated antihypertensive drug treatments to lower BP ([Table 1](#table1-2381468316671724){ref-type="table"}).^[@bibr14-2381468316671724][@bibr15-2381468316671724][@bibr16-2381468316671724][@bibr17-2381468316671724][@bibr18-2381468316671724][@bibr19-2381468316671724][@bibr20-2381468316671724][@bibr21-2381468316671724]--[@bibr22-2381468316671724]^ Ten studies were cost-utility analyses (CUA) or combined both CUA and a cost-effectiveness analysis (CEA)^[@bibr10-2381468316671724][@bibr11-2381468316671724]--[@bibr12-2381468316671724],[@bibr15-2381468316671724][@bibr16-2381468316671724]--[@bibr17-2381468316671724],[@bibr19-2381468316671724][@bibr20-2381468316671724][@bibr21-2381468316671724]--[@bibr22-2381468316671724]^ while three studies were CEA^[@bibr13-2381468316671724],[@bibr14-2381468316671724],[@bibr18-2381468316671724]^ ([Table 1](#table1-2381468316671724){ref-type="table"}). The intervention target (risk factor) examined was high BP. The remainder of this section describes the main findings.

###### 

Summary of Analytic Framework, Methods, and Model Features of Studies Included.
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  Study (Year)                                               Research Question                                                                                                        Perspective/Country                                Comparators                                                                                                           Target Population/Intervention                                                                 Time Horizon/Discount Rate                               Reported Baseline Results                                                                                                                                          Health States                            Study Design and Outcomes
  ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------- ---------------------------
  Kaambwa and others (2014)^[@bibr11-2381468316671724]^      LT CE of self-management of HPN                                                                                          UK NHS                                             Self-management of HPN versus usual care                                                                              66-year-old with HPN                                                                           Lifetime; 3.5% for both                                  Self-management of HPN was CE                                                                                                                                      Well                                     CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ICER £1624/QALY                                                                                                                                                    Stroke                                   QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          MI                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Angina                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          HF                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Death                                    
  Stevanovic and others (2014)^[@bibr14-2381468316671724]^   CE of lowering BP in patients with HPN and low CVD risk                                                                  Dutch HIS                                          Anti-HPN with HCTZ versus various combinations of HCTZ/Losartan (ACEIs) or HCTZ/ARBs versus no-treatment              Various age groups: 40, 50, 60, and 65; gender and various HPN groups                          10 year and lifetime; 4% for costs and 1.5% for health   Systolic BP reduction was found CE                                                                                                                                 Disease free-HPN                         CEA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       A 65-year-old:                                                                                                                                                     Acute CVD (nonfatal)                     LYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       • 10 year lifetime:                                                                                                                                                Stable CVD (nonfatal)                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       HCT €6032/LYG man or €12,345/LYG woman                                                                                                                             Fatal CVD                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       • Lifetime:                                                                                                                                                        Non-CVD death                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       HCT €3076/LYG man or €3074/LYG woman                                                                                                                                                                        
  Wu and others (2013)^[@bibr15-2381468316671724]^           CE of amlodipine (CCB) versus ARB in the prevention of stroke and MI                                                     Chinese third party payer                          Amlodipine (CCB) versus ARB                                                                                           Average 65-year-old cohort presenting HPN                                                      5 years, 3% for both                                     Amlodipine was the dominant strategy                                                                                                                               Disease free-HPN                         CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Stroke                                   QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Poststroke                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          MI                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Post-MI                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Dead                                     
  Kourlaba and others (2013)^[@bibr16-2381468316671724]^     CE of a BP lowering drug therapy in patients with mild-to-moderate HPN                                                   Greek third party payer                            Telmisartan/HCTZ compared to losartan/HCTZ and valsartan/HCTZ                                                         Average 57-year-old cohort presenting HPN; analyses undertaken by gender                       Lifetime, 3.5% for both                                  Telmisartan found to be CE                                                                                                                                         Disease free-HPN                         CEA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Males: €3002/QALY or €1765/LYG                                                                                                                                     Nonfatal MI                              CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Females: €10,856/QALY or €7076/LYG                                                                                                                                 Post-nonfatal MI                         LYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Stroke                                   QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Poststroke                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Death                                    
  Ekwunife and others (2013)^[@bibr17-2381468316671724]^     CE of drugs in the management of HPN                                                                                     Nigerian third party payer perspective for costs   Four classes of antihypertensive medications: HCTZ, pranolol (beta-blocker), lisinopril (ACE), and nifedipine (CCB)   Average 40-year-olds with HPN                                                                  30 years; 3% for both                                    In the low CVRS ACEI had highest (15,000 \$/QALY) NMB; however, in the medium and high risk CVRSs, CCB had highest WTP (15,000 and 12,500 \$/QALY, respectively)   Nonasymptomatic (disease free)           CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Stroke                                   NMB
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Nonfatal stroke                          EVPI
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CHD                                      US\$/QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Nonfatal CHD                             
  Wisloff and others (2012)^[@bibr12-2381468316671724]^      CE of various generic anti-HPN in the prevention of CVD                                                                  Norwegian HIS                                      CCB compared to no-treatment in various age groups and gender                                                         HPN patients at different age groups (40, 50, 60, and 70)                                      Lifetime, 4% for both                                    CCB/male was CE:                                                                                                                                                   Disease free-HPN                         CEA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       40: −€456,838/LYG                                                                                                                                                  Stroke                                   LYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       50: −€445,018/LYG                                                                                                                                                  Stroke-sequelae                          NHB
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       60: −€410,510/LYG                                                                                                                                                  AMI                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       70: −€352,875/LYG                                                                                                                                                  Angina                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       CCB/female was CE:                                                                                                                                                 HF                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       40: −€621,537/LYG                                                                                                                                                  Post-CVD                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       50: −€630,144/LYG                                                                                                                                                  Dead                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       60: −€588,999/LYG                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       70: −€465,906/LYG                                                                                                                                                                                           
  Baker and others (2012)^[@bibr22-2381468316671724]^        CE of initiating hypertension treatment with valsartan and then switching to generic losartan in the prevention of CVD   US third party payer perspective                   Two comparative analyses:                                                                                             Moderate HPN patients; SBP 160--179; aged 18 and older                                         20-year time horizon and 3% discount for both            Treatment of moderate hypertension was considered CE with an ICER of \$32,313/QALY or \$27,268/LYG                                                                 CVD event free with treated HPN          CVD event rates per arm
                                                                                                                                                                                                                                         1\. Continual valsartan versus continual losartan                                                                                                                                                                                                                             Switching treatment resulted in an ICER of £30,170/QALY and \$25,460/LYG                                                                                           Post-CVD with treated HPN                CEA
                                                                                                                                                                                                                                         2\. Continual valsartan versus valsartan switch to generic losartan                                                                                                                                                                                                                                                                                                                                                                              Death                                    CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   LYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   QALYs
  Granstrom and others (2012)^[@bibr21-2381468316671724]^    Long-term CE of candesartan versus losartan in the primary prevention of HPN                                             Swedish HIS                                        Candesartan versus losartan                                                                                           Average 62-year-old cohort presenting with HPN                                                 Lifetime, 3% for both                                    Candesartan was the dominant strategy                                                                                                                              Disease free-HPN                         CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          HF                                       QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Chronic IHD                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Post-MI                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PAD                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Poststroke                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Arrhythmia                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Dead                                     
  Perman and others (2011)^[@bibr13-2381468316671724]^       CE multi-intervention program versus pharmacological strategy                                                            Argentinian third party payer                      HPN program compared to usual care                                                                                    Two target groups: 65-year-old plus HPN; 65-year-old HPN and previous CVD                      Lifetime, 5% for both                                    The HPN program was cost-effective: US\$1124/LYG                                                                                                                   Acute myocardial event                   CEA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No event                                 LYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Death                                    
  Ekman and others (2008)^[@bibr19-2381468316671724]^        CE of irbesartan in combination with HCTZ in BP reduction                                                                Swedish third party payer                          Four strategies in male and female population: irbesartan; placebo; losartan; valsartan                               55-year-old male cohort presenting with HPN                                                    Lifetime, 3% for both                                    Irbesartan was CE when compared to placebo in males and females; ICERs of €3451/QALY and €7704/QALY respectively                                                   Disease free-HPN                         CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Losartan and valsartan were dominated by irbesartan in males and females                                                                                           Angina                                   QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          MI                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Post-MI                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CHF                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Stroke                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Poststroke                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Dead                                     
  Gandjour and Stock (2007)^[@bibr10-2381468316671724]^      CE of a national HPN program for patients with essential HPN and without CVD                                             German HIS                                         National program versus no program (for low- and high-risk population)                                                Various age groups (40--49, 50--59, and 60--69); patients with essential HPN and without CVD   Lifetime, 3% for both                                    National program is CE                                                                                                                                             Disease free-HPN                         CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       High-risk male:                                                                                                                                                    MI                                       QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       40: €800/QALY                                                                                                                                                      Stroke                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       50: €880/QALY                                                                                                                                                      Renal failure                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       60: €757/QALY                                                                                                                                                      Death                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       High-risk female:                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       40: −€17,347/QALY                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       50: −€26,987/QALY                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       60: −€1,263/QALY                                                                                                                                                                                            
  Montgomery and others (2003)^[@bibr12-2381468316671724]^   Effectiveness and CE of LT BP lowering                                                                                   UK Health Service perspective                      Anti-HPN treatment versus nontreatment                                                                                Various population cohorts: 30--39; 40--49; 50--59; 60--69; 70--79. Hypertensive population    Lifetime, 6% for costs and 1.5% for effects              Treatment found more CE than nontreatment                                                                                                                          Untreated                                CUA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ICER was higher for low-risk women compared to low-risk men                                                                                                        Treated T_se                             QALYs
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          U_cve_ua                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          T_cve_ua                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          T_se_cve_ua                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          U_cve_af                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          T_cve_af                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          T_se_cve_af                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Death                                    
  Nordmann and others (2003)^[@bibr20-2381468316671724]^     CE of ACE as HPN first-line therapy versus conventional therapy                                                          Canadian third party payer                         4 strategies:                                                                                                         40-year old male cohort presenting with HPN but without CVD                                    Lifetime, 5% for both                                    Unfavorable results of CE:                                                                                                                                         Disease free-HPN (with or without LVH)   CEA
                                                                                                                                                                                                                                         • Control or conventional therapy                                                                                                                                                                                                                                             ECG versus control: US\$0/QALY/LYG                                                                                                                                 CAD                                      CUA
                                                                                                                                                                                                                                         • ECG                                                                                                                                                                                                                                                                         EchoCar versus control: US\$200,000/QALY/LYG                                                                                                                       CVD                                      LYG
                                                                                                                                                                                                                                         • EchoCar                                                                                                                                                                                                                                                                     ACE versus control = US\$700,000/QALY or US\$525,000/LYG                                                                                                           CHF                                      QALYs
                                                                                                                                                                                                                                         • ACE                                                                                                                                                                                                                                                                                                                                                                                                                                            Dead                                     

Note: ACE = angiotensin-converting-enzyme inhibitor; AMI = acute myocardial infarction; ARB = angiotensin-II-receptor blocker; BP = blood pressure; CCB = calcium-channel blocker; CE = cost-effectiveness or cost-effective; CEA = cost-effectiveness analysis; CHF = congestive heart failure; CUA = cost-utility analysis; CVD = cardiovascular disease; EchoCar = echocardiography; EVPI = expected value of perfect information; HCTZ = hydrochlorothiazide; HF = heart failure; HIS = health insurance system; HPN = hypertension; IHD = ischemic heart disease; LYG = life year gained; MI = myocardial infarction; NHB = net health benefit; NMB = net monetary benefit; LT = long term; PAD = peripheral artery disease; T_se = treated, side-effects (health state); U_cve_ua = untreated, cardiovascular event, unaffected (health state); T_cve_ua = treated, cardiovascular event, unaffected (health state); T_se_cve_ua = treated, side-effects, cardiovascular event, unaffected (health state); U_cve_af = untreated, cardiovascular event, affected (health state); T_cve_af = treated, cardiovascular event, affected (health state); T_se_cve_af = treated, side-effect, cardiovascular event, affected (health state).

Problem Concept and Model Concept {#section3-2381468316671724}
---------------------------------

The decision problem and study objective(s) were stated in all the studies ([Table 2](#table2-2381468316671724){ref-type="table"}), and all evaluated CE from a health care payer perspective. The target decision-maker audience was made explicit in 10/13 studies as that of the health care payer, that is, including only the health effects experienced by patients receiving the intervention and costs for the medical services required to provide the intervention.^[@bibr23-2381468316671724]^ For the remaining studies,^[@bibr10-2381468316671724],[@bibr14-2381468316671724],[@bibr19-2381468316671724]^ the perspective was left implicit. Ekman and others^[@bibr19-2381468316671724]^ commented that the analysis was "in a Swedish health care setting", while Stevanovic and others^[@bibr14-2381468316671724]^ were interested "in the Dutch setting" and Gandjour and Stock^[@bibr10-2381468316671724]^ focused on those "insured by the German SHI," where SHI refers to the German Statutory Health Insurance.

###### 

Adherence to Good Practice Guidelines: Summary Results of Assessment.

![](10.1177_2381468316671724-table2)

  Information                                                                                                                                                                  Review Question                                                           Kaambwa and others (2014)^[@bibr11-2381468316671724]^   Stevanovic and others (2014)^[@bibr14-2381468316671724]^   Wu and others (2013)^[@bibr15-2381468316671724]^   Kourlaba and others (2013)^[@bibr16-2381468316671724]^   Ekwunife and others (2013)^[@bibr17-2381468316671724]^   Wisloff and others (2012)^[@bibr12-2381468316671724]^   Baker and others (2012)^[@bibr22-2381468316671724]^   Granstrom and others (2012)^[@bibr21-2381468316671724]^   Perman and others (2011)^[@bibr13-2381468316671724]^   Ekman and others (2008)^[@bibr19-2381468316671724]^   Gandjour and Stock (2007)^[@bibr10-2381468316671724]^   Montgomery and others (2003)^[@bibr12-2381468316671724]^   Nordmann and others (2003)^[@bibr20-2381468316671724]^
  ------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------
  *Dimension 1: Problem concept*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Decision problem                                                                                                                                                  Is there a written decision problem?                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Are the study's objective(s) consistent with the decision problem and the study's scope?                                                                                           Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Analytical perspective                                                                                                                                              Has the perspective being stated?                                                                           Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Target population                                                                                                                                              Has the target population being identified?                                                                      Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Health outcomes                                                                                                                          Are model's outcome(s) consistent with the perspective, scope and model's objective(s)?                                                Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Have any adverse effect(s) be captured?                                                                                                                                            No                                                                                           No                                                       Yes                                                     No                                                    No                                                       No                                                      No                                                     No                                                      No                                                       No                                                    No                                                     No                                                        No                             
  Interventions modeled                                                                                                                                            Are the options under evaluation clear?                                                                        Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Were the inclusion/exclusion of feasible options justified?                                                                                                                        Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Time horizon                                                                                                                                     Is it sufficient to reflect all important differences between options?                                                         Yes                                                      Yes                                                     No                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Have time horizon, duration of the treatment and the treatment effect(s) described and justified?                                                                                  Yes                                                                                          Yes                                                       No                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  *Dimension 2: Model concept*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Choice of model type                                                                                                                                              Was the unit of representation given?                                                                         Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Does interaction(s) among individuals need to be model? If yes, was this described?                                                                                                No                                                                                           No                                                        No                                                     No                                                    No                                                       No                                                      No                                                     No                                                      No                                                       No                                                    No                                                     No                                                        No                             
  Does the decision problem require a short time horizon?                                                                                                                            No                                                                                           No                                                        No                                                     No                                                    No                                                       No                                                      No                                                     No                                                      No                                                       No                                                    No                                                     No                                                        No                             
  Is it necessary to model time in discrete cycles?                                                                                                                                  Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Was a type of model discussed and chosen?                                                                                                                                          Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Model structure                                                                                                      Was the starting cohort defined by demographic and clinical characteristics affecting transition probabilities or state values?                            Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Were health states and transitions reflecting the biological or theoretical understanding of the disease modeled?                                                                  Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  *Dimension 3: Synthesis of evidence*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Patient heterogeneity                                                                                                                                        Was patient heterogeneity required/considered?                                                                     Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    No                                                      Yes                                                      No                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Data sources                                                                                                                        Were transition probabilities and intervention effects derived from representative data sources?                                            Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Were (all) methods and assumptions used to derive the model's inputs described?                                                                                                    Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Were parameters derived from observational studies controlled for confounding?                                                                                                     NA                                                                                           NA                                                        NA                                                     NA                                                    NA                                                       NA                                                      NA                                                     Yes                                                     NA                                                       NA                                                    NA                                                     Yes                                                       NA                             
  Was data's quality discussed?                                                                                                                                                      Yes                                                                                          Yes                                                       No                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  If expert opinion was used, were its methods described and justified?                                                                                                              No                                                                                           NA                                                        NA                                                     NA                                                    NA                                                      Yes                                                      NA                                                     NA                                                      NA                                                       NA                                                    No                                                     NA                                                       Yes                             
  Utilities (HSUV- weights and benefits)                                                                                                                 Are the utilities incorporated into the model appropriate?                                                               Yes                                                       NA                                                    Yes                                                   Yes                                                      Yes                                                      NA                                                     Yes                                                     Yes                                                      NA                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Is the source for the utility weights referenced?                                                                                                                                  Yes                                                                                          NA                                                       Yes                                                    Yes                                                   Yes                                                       NA                                                      Yes                                                    Yes                                                     NA                                                      Yes                                                    Yes                                                    Yes                                                      Yes                             
  Half cycle correction                                                                                                                                        Was the use of a half cycle correction stated?                                                                     Yes                                                       No                                                     No                                                    No                                                       No                                                      No                                                     No                                                      Yes                                                      No                                                    No                                                     Yes                                                       No                                                       Yes
  Resources including costs                                                                                                                         Were the costs used in the model justified and its sources described?                                                         Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Were discount rates reported and justified?                                                                                                                                        Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Communicating results                                                                                                                   Did the report presented results using non-technical language aided by figures or tables?                                               Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Parameter precision                                                                                                            Were mean value(s), distribution(s), source(s) of data and rationale for the supporting evidence described?                                      Yes                                                      Yes                                                     No                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                       No                                                        No
  *Dimension 4: Analysis of uncertainty*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Analysis of uncertainty                                                                                                                   Was analysis of uncertainty pertaining to the decision problem included and reported?                                                 Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Parameter estimation and uncertainty                                                                                                                   Were one-way or two-way DSA sensitivity analysis performed?                                                              No                                                       Yes                                                    Yes                                                    No                                                       No                                                      No                                                     Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Was a probabilistic sensitivity analysis (PSA) included?                                                                                                                           Yes                                                                                          Yes                                                       No                                                    Yes                                                   Yes                                                      Yes                                                      No                                                     Yes                                                     Yes                                                      No                                                    Yes                                                    No                                                        No                             
  Multivariate estimation and correlation                                                                                                                       Was correlation among parameters considered?                                                                      NA                                                        NA                                                     NA                                                    NA                                                       NA                                                      NA                                                     NA                                                      NA                                                       NA                                                    NA                                                     NA                                                        NA                                                        NA
  Structural uncertainty                                                                                                                        Were there any discussion/evidence of uncertainty in structural assumptions?                                                      Yes                                                      Yes                                                     No                                                    No                                                       No                                                      Yes                                                    No                                                      No                                                      Yes                                                    Yes                                                    Yes                                                       No                                                       Yes
  Other reporting of uncertainty analyses                                                                                                                               Was EVPI measured/discussed?                                                                              No                                                        No                                                     No                                                    No                                                      Yes                                                      No                                                     No                                                      No                                                       No                                                    No                                                     No                                                        No                                                        No
  If model calibration was used to estimate parameters, was uncertainty tested?                                                                                                      NA                                                                                           NA                                                        NA                                                     NA                                                    NA                                                       NA                                                      NA                                                     NA                                                      NA                                                       NA                                                    NA                                                     NA                                                        NA                             
  *Dimension 5: Model transparency and validation*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Transparency                                                                                                                                     Were the purpose, type and graphical description of the model provided?                                                        Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                       Yes
  Were the source(s) of funding and their role identified?                                                                                                                           Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     No                                                      Yes                                                    No                                                     Yes                                                      Yes                             
  Were data sources identified/described?                                                                                                                                            Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Were methods customized to specific application(s) and settings?                                                                                                                   Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Were the effects of uncertainty measured?                                                                                                                                          Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Were limitations acknowledged/discussed?                                                                                                                                           Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Was any reference to the availability of model's documentation at request or terms and conditions to access it?                                                                    No                                                                                           No                                                        No                                                     No                                                    No                                                       No                                                      No                                                     No                                                      No                                                       No                                                    No                                                     No                                                        No                             
  Was there any evidence of model's face validity?                                                                                                                                   Yes                                                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Validation                                                                                                                                        Was internal validity (verification or technical validity) assessed?                                                          Yes                                                      Yes                                                    Yes                                                   Yes                                                      Yes                                                      Yes                                                    Yes                                                     Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                                                        No
  Was cross-validation (external consistency) assessed?                                                                                                                              Yes                                                                                          Yes                                                       No                                                    Yes                                                   Yes                                                       No                                                      No                                                     No                                                      Yes                                                     Yes                                                    Yes                                                    Yes                                                      Yes                             
  Was external validity assessed                                                                                                                                                     No                                                                                           Yes                                                       No                                                     No                                                    No                                                       No                                                      No                                                     No                                                      No                                                       No                                                    No                                                     No                                                        No                             
  Was the model's predictive validity assessed?                                                                                                                                      NA                                                                                           NA                                                        NA                                                     NA                                                    NA                                                       NA                                                      NA                                                     NA                                                      NA                                                       NA                                                    NA                                                     NA                                                        NA                             

For all studies, the target population was individuals with hypertension or at risk of developing hypertension ([Tables 1](#table1-2381468316671724){ref-type="table"} and [2](#table2-2381468316671724){ref-type="table"}), frequently stratified by gender, presence of hypertension, age groups, and mean age. The target population was always modeled as closed (reflecting members entering only at the start of the analysis).

Despite all the studies sharing a common aim, namely, primary prevention of CVD via lowering BP, these economic models compared a wide range of interventions and presented their results using outcome measures such as QALYs,^[@bibr10-2381468316671724][@bibr11-2381468316671724]--[@bibr12-2381468316671724],[@bibr15-2381468316671724][@bibr16-2381468316671724]--[@bibr17-2381468316671724],[@bibr19-2381468316671724][@bibr20-2381468316671724][@bibr21-2381468316671724]--[@bibr22-2381468316671724]^ life years gained (LYG),^[@bibr13-2381468316671724],[@bibr14-2381468316671724],[@bibr16-2381468316671724],[@bibr18-2381468316671724],[@bibr20-2381468316671724],[@bibr22-2381468316671724]^ net health benefits (NHB),^[@bibr18-2381468316671724]^ net monetary benefits (NMB),^[@bibr17-2381468316671724]^ and expected value of perfect information (EVPI)^[@bibr17-2381468316671724]^ ([Table 1](#table1-2381468316671724){ref-type="table"}).

Side effects were modeled in only one study.^[@bibr15-2381468316671724]^ Four studies^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr14-2381468316671724],[@bibr22-2381468316671724]^ acknowledged the lack of adverse events as a limitation of their results due to lack of data. Two studies argued that since "previous clinical trials found that first-line hypertensive drugs do not have more side effects than placebo"^[@bibr13-2381468316671724]^ or they have "mild side effects,"^[@bibr19-2381468316671724]^ there was no need to model adverse effects. Similarly another study argued that fatal side effects would have been already captured in the clinical trials via the measure of effectiveness.^[@bibr18-2381468316671724]^

All the studies commented on the reasons for the selection of their comparators, where their choice of comparators seems to have been governed by the scope of the study. Two studies acknowledged as a limitation the exclusion of relevant comparator(s) arguing that there may be more relevant comparators not included.^[@bibr19-2381468316671724],[@bibr21-2381468316671724]^ Furthermore, the "do nothing" option was considered in four of the studies.^[@bibr10-2381468316671724],[@bibr14-2381468316671724],[@bibr18-2381468316671724],[@bibr19-2381468316671724]^

All the studies used Markov models and included a figure showing the model structure; in one study,^[@bibr13-2381468316671724]^ the structure of the Markov model shown in the figure did not seem to reflect the structure of the model described in the text. The model structures accounted for both acute and chronic health states. Five studies made explicit reference to how the structure of their models was defined either by using an existing generic model,^[@bibr18-2381468316671724]^ being based on disease progression,^[@bibr10-2381468316671724],[@bibr11-2381468316671724]^ or consisting of health states designed to reflect the course and history of CVD events.^[@bibr22-2381468316671724]^ One study reported that "health states in the Markov model are based on cardiovascular events measured in the previously reported registry study."^[@bibr21-2381468316671724]^ For the remaining studies it was inferred that the model structure was based on disease progression.

A lifetime time horizon was adopted in all but two studies: of these, one used a 5-year^[@bibr15-2381468316671724]^ time horizon for a population aged 65 years while the second used 20 years for a population aged 18 and older.^[@bibr22-2381468316671724]^ The 5-year time horizon was justified as matching the 5-year time span given to social security authorities in China for budget planning,^[@bibr15-2381468316671724]^ while the 20-year time horizon was not discussed.^[@bibr22-2381468316671724]^ Cycle length, though rarely justified in the studies, was always 1 year. Only one study^[@bibr10-2381468316671724]^ justified their choice as most of the data used in their model referred to a 1-year period.

Synthesis of Evidence {#section4-2381468316671724}
---------------------

Patient heterogeneity was considered in most of the studies; results were presented by age cohorts^[@bibr10-2381468316671724],[@bibr12-2381468316671724],[@bibr14-2381468316671724],[@bibr15-2381468316671724],[@bibr18-2381468316671724]^ and gender.^[@bibr10-2381468316671724][@bibr11-2381468316671724]--[@bibr12-2381468316671724],[@bibr14-2381468316671724][@bibr15-2381468316671724]--[@bibr16-2381468316671724],[@bibr18-2381468316671724],[@bibr19-2381468316671724],[@bibr21-2381468316671724]^ Some studies added further analyses based on the risk of CVD,^[@bibr10-2381468316671724],[@bibr12-2381468316671724],[@bibr17-2381468316671724]^ scenarios of SBP reduction,^[@bibr14-2381468316671724],[@bibr19-2381468316671724]^ smoking,^[@bibr14-2381468316671724]^ and patient adherence.^[@bibr14-2381468316671724],[@bibr22-2381468316671724]^ The risks of secondary events were modeled in seven of the studies, for example, the risk of a further stroke after a first stroke.^[@bibr12-2381468316671724][@bibr13-2381468316671724]--[@bibr14-2381468316671724],[@bibr18-2381468316671724][@bibr19-2381468316671724][@bibr20-2381468316671724]--[@bibr21-2381468316671724]^ In some instances, assumptions were acknowledged; for example, the study by Stevanovic and others^[@bibr14-2381468316671724]^ assumed the risk of secondary events to be equal to the risk of a first nonfatal CVD event. The authors acknowledged that this would lead to an underestimation of the CVD risk, and so an increased risk of death in patients experiencing nonfatal CVD events was adopted.^[@bibr14-2381468316671724]^ In Wisloff and others,^[@bibr18-2381468316671724]^ secondary nonfatal events were allowed, and a patient experiencing a secondary event was assumed to be in a health state that was worse than the state they were already in. For example, a patient with stroke sequelae that experiences a myocardial infarction (MI) will have the risk and costs associated with the stroke sequelae and not those related to MI. Perman and others^[@bibr13-2381468316671724]^ utilized expert opinion in the assessment of the risk of secondary events. Montgomery and others,^[@bibr12-2381468316671724]^ due to a lack of data, assumed that any second cardiovascular event was fatal and acknowledged this as a limitation. Some studies that did not use separate states to model secondary events^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr22-2381468316671724]^ captured the increased mortality from secondary events through the mortality rate of patients surviving CVD events. Few of the studies acknowledged the lack of epidemiological data to model secondary events as a limitation.^[@bibr11-2381468316671724],[@bibr22-2381468316671724]^

All studies applied discounting to their results: a discount rate of 3% was most common for costs and benefits;^[@bibr10-2381468316671724],[@bibr15-2381468316671724],[@bibr17-2381468316671724],[@bibr19-2381468316671724],[@bibr21-2381468316671724],[@bibr22-2381468316671724]^ two studies used a different discount rate for costs and benefits (Stevanovic and others^[@bibr14-2381468316671724]^ used 4% and 1.5%, while Montgomery and others^[@bibr12-2381468316671724]^ used 6% and 1.5%, respectively; [Table 1](#table1-2381468316671724){ref-type="table"}). Information on the parameters used as inputs were most frequently presented in tables showing mean values and the type of distribution(s) while some studies also included 95% confidence intervals or range intervals.^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr20-2381468316671724]^ The methods used to report the sources of information varied from reporting a detailed list of sources per parameter in a table to mentioning the sources of data in the main text.

Analysis of Uncertainty {#section5-2381468316671724}
-----------------------

The studies examined and reported uncertainty surrounding their identified outcomes through sensitivity analysis (SA). Uncertainty in parameter estimates was most commonly handled through deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). Five studies used only one-way DSA,^[@bibr12-2381468316671724],[@bibr15-2381468316671724],[@bibr19-2381468316671724],[@bibr20-2381468316671724],[@bibr22-2381468316671724]^ while another four^[@bibr11-2381468316671724],[@bibr16-2381468316671724][@bibr17-2381468316671724]--[@bibr18-2381468316671724]^ only used PSA. Only one study measured EVPI^[@bibr17-2381468316671724]^ ([Table 2](#table2-2381468316671724){ref-type="table"}).

Elements pertaining to structural uncertainty (SU) were acknowledged as such in six studies.^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr13-2381468316671724],[@bibr14-2381468316671724],[@bibr19-2381468316671724],[@bibr20-2381468316671724]^ Most commonly SU was assessed through SA by varying the time horizon,^[@bibr11-2381468316671724]^ the duration of the effectiveness of the treatment,^[@bibr11-2381468316671724],[@bibr14-2381468316671724]^ the discount rate,^[@bibr13-2381468316671724],[@bibr19-2381468316671724]^ or by using alternative measures of outcomes.^[@bibr19-2381468316671724]^ One study examined the impact of assumptions related to secondary events.^[@bibr18-2381468316671724]^ Lack of clinical evidence for key parameters such as the treatment effect of drugs^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr14-2381468316671724]^ was identified as a source of SU. Two studies acknowledged that they could have included more relevant comparators had they had more information,^[@bibr19-2381468316671724],[@bibr21-2381468316671724]^ and another two acknowledged that they had excluded a potentially relevant state due to lack of epidemiological data^[@bibr10-2381468316671724]^ or insufficient evidence on its relevance.^[@bibr20-2381468316671724]^

The decision about which events and health states were included was partially discussed. Some studies acknowledged that they subdivided a health state^[@bibr11-2381468316671724]^ (CHD into MI, HF, and angina), or excluded a potentially relevant health state^[@bibr15-2381468316671724]^ (combined stroke and MI event). All studies included chronic health states (post events); however, few discussed having modeled the progression of disease.^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr22-2381468316671724]^ Most frequently, the studies acknowledged the adoption of assumptions, that is, assuming the duration of treatment effects to be lifetime or as long as the time horizon in the model,^[@bibr10-2381468316671724],[@bibr11-2381468316671724],[@bibr14-2381468316671724]^ or 5 years^[@bibr19-2381468316671724]^ or varied.^[@bibr21-2381468316671724]^

Model Transparency and Validation {#section6-2381468316671724}
---------------------------------

All the studies included a graphical description of the Markov model they used ([Table 2](#table2-2381468316671724){ref-type="table"}). Sources of funding were identified in 11 studies: five were funded by the pharmaceutical industry,^[@bibr14-2381468316671724][@bibr15-2381468316671724]--[@bibr16-2381468316671724],[@bibr19-2381468316671724],[@bibr21-2381468316671724],[@bibr22-2381468316671724]^ one benefited from joint funds from government and pharmaceutical sources,^[@bibr18-2381468316671724]^ three were exclusively government-funded,^[@bibr11-2381468316671724],[@bibr12-2381468316671724],[@bibr20-2381468316671724]^ and one was privately funded.^[@bibr17-2381468316671724]^ None of the studies stated any means for accessing more detailed information about the model. All the studies had a clear policy context with an explicit statement of funder and developer.

Validation, according to guidelines,^[@bibr24-2381468316671724]^ is a set of methods for judging the accuracy of a model in making relevant predictions; in other words, validation helps readers understand what a model does and how it does it. In this review, we checked for five main types of validation. All the studies were subjected to face validity checks (having been peer reviewed and published in a journal) and they were subjected to verification (internal validity checking). The methods used were justified to a greater or lesser extent in each study. All studies undertook SA of parameters as a way to double check that the direction and magnitude of their outputs were as expected.

In terms of cross-validation, results were mixed. Eight studies^[@bibr10-2381468316671724][@bibr11-2381468316671724][@bibr12-2381468316671724][@bibr13-2381468316671724]--[@bibr14-2381468316671724],[@bibr17-2381468316671724],[@bibr19-2381468316671724],[@bibr20-2381468316671724]^ examined different models that addressed the same problem and compared their results; however, the level of detail provided varied. Five studies presented limited or no evidence of cross-validation;^[@bibr15-2381468316671724],[@bibr16-2381468316671724],[@bibr18-2381468316671724],[@bibr21-2381468316671724],[@bibr22-2381468316671724]^ only Wisloff and others^[@bibr18-2381468316671724]^ undertook an exercise of external validation by comparing their estimated lifetimes to those reported by Statistics Norway and in doing so they found that the input into their model needed to be adjusted to fit Norwegian mortality data. An assessment of predictive validity was not included in any of the studies considered.

Discussion {#section7-2381468316671724}
==========

Using a previously developed practical framework,^[@bibr6-2381468316671724]^ we have critically evaluated how 13 published economic evaluations conformed to contemporaneous good practice guidelines. We found that published economic evaluations of interventions aimed at lowering BP in patients with hypertension, as part of a primary prevention strategy of CVD, demonstrated limited compliance to DAM guidelines, which has usually been explained by lack of data or imperfect data. This was particularly apparent in the assessment of SU (or lack of) and model external validation.

This review identified common grounds in terms of the adherence to, and use of, guidelines. The conceptual modeling in all the studies included in this review was based on a disease process where the focus was on the definition of the health states (conditions) as opposed to treatment (pathways) received and where the decision problem posed required the evaluation of the reduction in the risk of developing hypertension, thus explaining the use of Markov models.

It has been argued that alternative model structures can lead to variations in model predictions,^[@bibr25-2381468316671724]^ most importantly, in the context of a primary prevention strategy, an inappropriate model structure may lead to poorly informed policy decisions, resulting in inefficient allocation of scarce resources.^[@bibr26-2381468316671724]^ Models are by nature sensitive to choices made at every single stage during the model development process (i.e., model concept, model structure). There will almost always be more than one set of choices, and for this reason, guidelines have suggested assessing the extent to which model predictions are influenced by the choices made during the model development process and have suggested methods to do so, such as scenario analyses.^[@bibr27-2381468316671724],[@bibr28-2381468316671724]^

Lifetime time horizons should be adopted (or be justified when constrained by the cohort's lifetime), or at the very least, time horizons should be "long enough" to capture relevant differences in outcomes across strategies.^[@bibr23-2381468316671724]^ Lack of data or imperfect data still poses important challenges for researchers, for example, when modeling the risk of secondary events and disease progression or to attempt the assessment of model validity. Even though elements pertaining to SU were identified by various authors, the assessment of SU cannot be considered common practice in this particular clinical area and additional guidelines are still needed to aid researchers identifying and quantifying SU.

External validity still poses a challenge to researchers and, more importantly, to future guidelines due to the apparent unavailability of actual extra data (from RCT or patient-level data) to undertake the exercise. It has been suggested that instead of using all the data available to create a model, some data be set aside to use during the validation process (e.g., one third of the data).^[@bibr29-2381468316671724]^ This may or may not always be possible, and will depend on how much data a researcher has to build a model.

Studies included in this review shared similar research questions and yet there was a great diversity in the structures of the Markov models used. Some of these were simple and some more complex, and they were generally developed with limited justification.^[@bibr26-2381468316671724]^ These indicate, as suggested by Squires and other,^[@bibr30-2381468316671724]^ that the methods for the development of the model structure are still underdeveloped. This can lead to errors including poor validity, credibility, and no basis for model verification and the analysis of structural uncertainty.

Caro and Möller^[@bibr29-2381468316671724]^ described the above as the disposable approach to modeling: models are built for a single use, focused on a particular product for a relatively short time. This explains---to some extent---the reduced motivation for undertaking model validation.^[@bibr29-2381468316671724]^ Future research should examine whether the development of "generic models," or as proposed by Caro and Möller, the development of multi-use models over time, can capture sufficient detail to be realistic and avoid particulars for which there are no data, and thereby allow the economic evaluation of interventions targeting CVD in any setting, and whether this will bridge the knowledge gap and, most importantly, allow ease of comparison between the results obtained from different studies.

This is the first study that has critically reviewed compliance to DAM guidelines using a previously developed practical framework. It has covered more than a decade of published DAM studies of interventions aimed at lowering BP in patients with hypertension. We believe the inclusion of recent studies from European, American, and Asian countries has helped reflect current practice worldwide.

The exclusion criteria adopted may be considered as limitation; however, these were required to guarantee consistency in the analysis. Furthermore, a negligible number of non-English-language studies were identified pertaining to applied studies. The fact that none of the studies included was published after the release of the "five-dimension framework" and the selection of one particular clinical area (and any impact on generalizability this may have) may also be considered a limitation.

Our findings seem in line with recent debate around the methodological challenges being faced by DAM where model validation and SU have been identified as fundamental problems due to the lack of motivation, time, and data to validate models and, in the case of SU, a lack of methods.^[@bibr29-2381468316671724]^
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